Two Seas Capital LP Has $44.04 Million Stake in Esperion Therapeutics, Inc. $ESPR

Two Seas Capital LP raised its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 22.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,902,521 shares of the biopharmaceutical company’s stock after acquiring an additional 2,152,797 shares during the period. Esperion Therapeutics comprises about 0.9% of Two Seas Capital LP’s investment portfolio, making the stock its 13th largest holding. Two Seas Capital LP owned about 4.98% of Esperion Therapeutics worth $44,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Esperion Therapeutics by 23.6% in the fourth quarter. Vanguard Group Inc. now owns 14,945,454 shares of the biopharmaceutical company’s stock valued at $55,298,000 after acquiring an additional 2,853,005 shares during the period. Geode Capital Management LLC grew its stake in Esperion Therapeutics by 20.8% in the fourth quarter. Geode Capital Management LLC now owns 5,737,651 shares of the biopharmaceutical company’s stock valued at $21,234,000 after acquiring an additional 986,255 shares during the period. Marshall Wace LLP grew its stake in Esperion Therapeutics by 46.2% in the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after acquiring an additional 1,679,294 shares during the period. AIGH Capital Management LLC grew its stake in Esperion Therapeutics by 33.3% in the fourth quarter. AIGH Capital Management LLC now owns 4,000,000 shares of the biopharmaceutical company’s stock valued at $14,800,000 after acquiring an additional 1,000,000 shares during the period. Finally, Royce & Associates LP grew its stake in Esperion Therapeutics by 57.0% in the fourth quarter. Royce & Associates LP now owns 3,601,523 shares of the biopharmaceutical company’s stock valued at $13,326,000 after acquiring an additional 1,308,035 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $3.13 on Friday. Esperion Therapeutics, Inc. has a one year low of $0.95 and a one year high of $4.18. The firm has a market cap of $805.76 million, a price-to-earnings ratio of -52.17, a price-to-earnings-growth ratio of 2.54 and a beta of 1.07. The stock’s 50-day moving average is $2.67 and its 200-day moving average is $3.13.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.The company had revenue of $80.10 million for the quarter, compared to the consensus estimate of $84.52 million. On average, equities analysts expect that Esperion Therapeutics, Inc. will post 0.05 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Citizens Jmp lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Piper Sandler lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Needham & Company LLC lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Jefferies Financial Group lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.54.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.